AOD-9604 Weight Loss: What the Trials Actually Showed

The short version

If you take one thing from this page, take this: when AOD-9604 weight loss was tested in people, it did not work better than a placebo. That is not a hedge or a technicality — it is the central finding, and it leads this page because an honest summary requires it to. The pivotal human obesity trial did not produce statistically significant weight loss versus a dummy treatment, and the company shelved the program around 2007 ^{[9] [10]}.

The reason the internet still calls it a "fat-loss peptide" is that the animal data really is strong. In obese mice, the compound reduced body weight and fat and shifted the body toward burning fat ^{[1] [2]}. But a result in mice is a starting line, not a finish line. About 900 overweight adults were studied, and the finish line — real weight loss in people — was not crossed ^{[5] [9]}. Below, the rodent promise and the human result are set side by side so the gap is impossible to miss.

What the rodent studies showed

The animal case for fat loss is genuinely good, which is exactly why this disappoints. After 14 days of chronic treatment, both human growth hormone and AOD-9604 reduced body weight and fat in obese mice and raised the expression of the beta-3 adrenergic receptor — the fat-cell switch for burning energy — back toward lean-mouse levels ^[1]. A second study confirmed that chronic treatment with the C-terminal fragment increased fat oxidation and produced weight loss in obese mice ^[2]. Mechanistically, the compound also blocks acetyl-CoA carboxylase, the enzyme that builds new fat, so it works from both directions — less fat made, more fat burned ^[4]. On paper, in a mouse, this is a fat-loss drug. The keyword that qualifies every sentence here is the species.

What the human trials showed

Now the human record. Across roughly six randomised, double-blind, placebo-controlled trials — about 900 obese adults, oral doses from 0.25 mg to 54 mg per day, durations from 7 days to 24 weeks — AOD-9604 was well tolerated, with side effects hard to tell apart from placebo ^[5]. That tolerability is real and worth stating. But tolerability is not the same as working. The pivotal Phase IIb obesity trial, the one designed to prove weight loss, did not demonstrate statistically significant weight loss versus placebo, and the obesity development program was discontinued ^{[9] [10]}. The compound was never approved for weight loss or anything else ^[9]. Reviews of obesity pharmacotherapy now file AOD-9604 among the lipolytic growth-hormone-fragment candidates that looked promising and did not deliver clinical benefit ^{[8] [10]}.

A note on the hype

A few corrections worth making plainly, because the marketing makes the opposite claims. First, the foundational literature characterised this fragment as primarily antilipogenic — it inhibits fat synthesis — rather than as a direct fat-melter, so even the mechanism is more modest than "fat-burning peptide" suggests ^{[3] [4]}. Second, there is no such thing as spot reduction here: no human trial supports localised fat loss, and injecting near a "problem area" does not melt fat there — bodies simply do not lose fat by injection location. Third, the people who report any visible change almost always credit a calorie deficit and training running alongside, which makes the peptide impossible to credit. Set expectations against the human evidence, which is weak, not against the rodent data, which does not transfer.